Growth Metrics

Keros Therapeutics (KROS) Preferred Shares Issued (2020)

Keros Therapeutics posted quarterly Preferred Shares Issued of $56.0 million for Q1 2020.

Keros Therapeutics (KROS) has 1 years of Preferred Shares Issued data on file, last reported at $56.0 million in Q1 2020.

  • For the quarter ending Q1 2020, Preferred Shares Issued changed N/A year-over-year to $56.0 million; the trailing twelve-month figure through Dec 2020 stood at $56.0 million (changed N/A YoY), and the FY2020 full-year result was $56.0 million, changed N/A from the prior year.
  • Preferred Shares Issued for Q1 2020 stood at $56.0 million.
  • Across five years, Preferred Shares Issued topped out at $56.0 million in Q1 2020 and bottomed at $56.0 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Keros Therapeutics 403.85 Mn 116.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2020 56.00 Mn
Mar 31, 2020 56.00 Mn